National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Argipressin acetate (Embesin®)is indicated for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years.  A catecholamine refractory hypotension is present if the mean arterial blood pressure cannot be stabilised to target despite adequate volume substitution and application of catecholamines.


NCPE Assessment Process Complete
Rapid review commissioned 16/09/2019
Rapid review completed 11/10/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that argipressin acetate (Embesin®) not be considered for reimbursement at the submitted price*.


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.